-
2022-500764-35-00
6
2022-10-13
Patients with advanced HER2-negative, hormone receptor positive (HER2n
-
2023-510376-31-00
4
2022-10-05
Cystic fibrosis
-
2023-508129-28-00
9
2022-09-28
Pediatric patients with Philadelphia chromosome positive chronic myelo
-
2023-509278-41-00
5
2022-07-04
Early Stage Follicular LymphOma
-
2023-509277-22-00
4
2022-06-22
Bronchiectasis
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2023-503267-42-00
5
2022-06-10
Patients with a histological diagnosis of mismatch- repair deficient h
-
2024-516331-27-00
3
2022-06-10
Participants with BRAF and/or NRAS mutation positive tumors
-
2023-503651-10-00
7
2022-05-17
Male and female participants ≥ 18 years of age with advanced or
metast
-
2024-513412-10-00
9
2022-05-11
Anaplastic Large Cell Lymphoma (ALCL)
-
2023-507119-36-00
5
2022-05-09
Malignant melanoma of the skin in patients with locally advanced and f
-
2024-511780-28-00
4
2022-05-05
Patients with presumed and previously untreated advanced stage ovarian
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2022-502425-18-00
5
2022-04-19
Adenocarcinoma of the prostate
-
2024-511264-89-00
4
2022-04-11
Glioblastoma
-
2023-504599-10-00
4
2022-03-29
Chronic lymphocytic leukemia recurrent
-
2024-516504-42-00
5
2022-03-05
Respiratory distress syndrome in preterm infants
-
2023-508963-58-00
4
2022-01-31
Symptomatic hypertrophic cardiomyopathy (HCM)
-
2024-512174-10-00
5
2021-11-11
metastatic colorectal cancer
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-513723-16-00
4
2021-10-21
metastatic colorectal cancer
-
2023-509863-26-00
11
2021-04-29
Liver cirrhosis
-
2024-513950-32-00
4
2020-12-15
Intermediate stage hepatocellular carcinoma (HCC)
-
2024-514010-12-00
1
2020-12-03
Advanced Malignancies